Carcinoma In Situ
NCI Definition: A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion. 
Carcinoma in situs most frequently harbor alterations in TP53, PIK3CA, KRAS, ESR1, and EGFR .
TP53 Mutation, PIK3CA Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and PIK3CA Codon 1047 Missense are the most common alterations in carcinoma in situ .
There are 2 clinical trials for carcinoma in situ, of which 2 are open and 0 are completed or closed. Of the trials that contain carcinoma in situ as an inclusion criterion, 2 are phase 2 (2 open).
Bcg solution, linrodostat, and nivolumab are the most common interventions in carcinoma in situ clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.